Geodon: Effective Atypical Antipsychotic for Symptom Control
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.71 | $54.25 (0%) | 🛒 Add to cart |
| 30 | $1.91 | $81.37 $57.26 (30%) | 🛒 Add to cart |
| 60 | $1.42 | $162.74 $85.39 (48%) | 🛒 Add to cart |
| 90 | $1.19 | $244.10 $107.49 (56%) | 🛒 Add to cart |
| 120 | $0.95 | $325.47 $114.52 (65%) | 🛒 Add to cart |
| 180 | $0.86 | $488.21 $154.70 (68%) | 🛒 Add to cart |
| 270 | $0.80 | $732.31 $216.98 (70%) | 🛒 Add to cart |
| 360 | $0.76
Best per pill | $976.41 $275.24 (72%) | 🛒 Add to cart |
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.62 | $46.21 (0%) | 🛒 Add to cart |
| 20 | $3.16 | $92.42 $63.29 (32%) | 🛒 Add to cart |
| 30 | $2.21 | $138.63 $66.30 (52%) | 🛒 Add to cart |
| 60 | $1.59 | $277.25 $95.43 (66%) | 🛒 Add to cart |
| 90 | $1.37 | $415.88 $123.56 (70%) | 🛒 Add to cart |
| 120 | $1.27 | $554.51 $152.69 (72%) | 🛒 Add to cart |
| 180 | $1.22 | $831.76 $218.99 (74%) | 🛒 Add to cart |
| 270 | $1.19 | $1247.64 $320.45 (74%) | 🛒 Add to cart |
| 360 | $1.17
Best per pill | $1663.52 $419.90 (75%) | 🛒 Add to cart |
Geodon (ziprasidone) is an atypical antipsychotic medication indicated for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar disorder. It functions by modulating dopamine and serotonin activity in the brain, contributing to a balanced neurochemical environment. This medication is available in both oral capsule and intramuscular injection formulations, offering flexibility in administration based on clinical needs and patient circumstances. Geodon is recognized for its efficacy in reducing positive and negative symptoms of schizophrenia, as well as stabilizing mood in bipolar presentations. Its pharmacokinetic profile supports twice-daily dosing, though careful attention must be paid to administration with food to ensure optimal absorption.
Features
- Active ingredient: ziprasidone hydrochloride
- Available formulations: oral capsules (20 mg, 40 mg, 60 mg, 80 mg) and intramuscular injection (20 mg/mL after reconstitution)
- Mechanism: dopamine D2 and serotonin 5-HT2A receptor antagonist
- Half-life: approximately 7 hours
- Administration: oral capsules must be taken with at least 500 kcal meal for adequate absorption
- FDA-approved indications: schizophrenia (acute and maintenance treatment), bipolar mania (monotherapy and adjunct)
Benefits
- Reduces frequency and severity of psychotic symptoms including hallucinations, delusions, and disorganized thinking
- Helps stabilize mood swings and decrease manic symptoms in bipolar disorder
- Lower risk of extrapyramidal symptoms compared to typical antipsychotics
- Minimal weight gain potential relative to some other atypical antipsychotics
- Flexible dosing options accommodate individual patient response and tolerance
- Rapid-acting intramuscular formulation available for acute agitation management
Common use
Geodon is primarily prescribed for the management of schizophrenia in adults, helping to control both positive symptoms (such as hallucinations and delusions) and negative symptoms (including social withdrawal and flattened affect). In bipolar disorder, it is used to treat acute manic or mixed episodes, either as monotherapy or in combination with lithium or valproate. The intramuscular formulation is specifically utilized for the rapid control of agitation in schizophrenic patients when immediate intervention is necessary. Off-label uses may include adjunctive treatment in major depressive disorder, though this application requires careful risk-benefit consideration by treating physicians.
Dosage and direction
For schizophrenia treatment, the initial oral dosage is typically 20 mg twice daily with meals. Dosage may be increased gradually to a target range of 60-80 mg twice daily, with maximum recommended dose of 160 mg daily. For bipolar mania, initial dosing is 40 mg twice daily with food, potentially increasing to 60 or 80 mg twice daily based on response and tolerance. Intramuscular administration for acute agitation is 10-20 mg, which may be repeated every 4 hours up to maximum 40 mg daily. All oral doses must be taken with at least 500 kcal meals to ensure approximately double the bioavailability compared to fasting state. Dose adjustments are necessary in hepatic impairment but not typically required for renal impairment alone.
Precautions
Patients should be monitored regularly for QT prolongation, as Geodon may increase this interval in dose-related fashion. Baseline and periodic electrocardiograms are recommended, particularly in those with pre-existing cardiac conditions or concomitant QT-prolonging medications. Neuroleptic malignant syndrome, though rare, requires immediate discontinuation if suspected. Tardive dyskinesia may develop with chronic use and can become irreversible. Orthostatic hypotension may occur, especially during initial dose titration. Patients should be cautioned about operating machinery until they know how Geodon affects them. Glucose monitoring is advised due to potential hyperglycemia and diabetes risk. Elderly patients with dementia-related psychosis treated with antipsychotics show increased mortality risk.
Contraindications
Geodon is contraindicated in patients with known hypersensitivity to ziprasidone or any component of the formulation. It must not be used in combination with other drugs known to prolong QT interval, including but not limited to quinidine, dofetilide, sotalol, thioridazine, chlorpromazine, droperidol, pimozide, moxifloxacin, mefloquine, pentamidine, arsenic trioxide, dolasetron mesylate, probucol, or tacrolimus. Contraindication exists for patients with history of QT prolongation (including congenital long QT syndrome) and those with recent acute myocardial infarction or uncompensated heart failure. Concomitant use with potent CYP3A4 inhibitors such as ketoconazole is contraindicated.
Possible side effect
Common adverse reactions (≥5% and at least twice placebo) include somnolence (14%), respiratory tract infection (8%), extrapyramidal symptoms (8%), dizziness (8%), nausea (8%), and akathisia (8%). Other reported side effects include constipation, dyspepsia, rash, increased cough, orthostatic hypotension, tachycardia, weight gain, and blurred vision. Less frequent but serious side effects may include QT prolongation, neuroleptic malignant syndrome, tardive dyskinesia, seizures, hyperglycemia, diabetes mellitus, dysphagia, and leukopenia. Injection site pain may occur with intramuscular administration. Many side effects are dose-dependent and may diminish with continued therapy or dosage adjustment.
Drug interaction
Geodon is metabolized primarily by aldehyde oxidase and CYP3A4, creating significant interaction potential. Potent CYP3A4 inhibitors (ketoconazole, itraconazole) increase ziprasidone concentrations and are contraindicated. Carbamazepine, a CYP3A4 inducer, decreases ziprasidone exposure by approximately 35%. Concomitant use with other central nervous system depressants (alcohol, benzodiazepines, opioids) may enhance sedative effects. Geodon may enhance hypotensive effects of antihypertensive medications. Due to QT prolongation risk, concomitant use with other QT-prolonging drugs is contraindicated. Geodon may antagonize levodopa and dopamine agonists. Caution is advised with medications that affect electrolyte balance (diuretics) due to potential exacerbation of QT effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is close to the time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take double or extra doses to make up for a missed dose. If multiple doses are missed, patients should contact their healthcare provider for guidance on resuming therapy, as dosage re-titration may be necessary. Consistency in administration with food is important even when managing missed doses to maintain stable pharmacokinetics.
Overdose
Symptoms of overdose may include sedation, tremor, hypotension, and QT prolongation. In cases of suspected overdose, immediate medical attention should be sought. There is no specific antidote for ziprasidone overdose. Management should include supportive measures and close cardiac monitoring, particularly for QT interval changes. Gastric lavage may be considered if presentation is early after ingestion. Activated charcoal may be administered if the patient presents within one hour of ingestion. Hemodialysis is unlikely to be beneficial due to ziprasidone’s high protein binding and large volume of distribution. Cardiovascular monitoring should continue for at least 24 hours due to the potential for delayed effects.
Storage
Store Geodon capsules at room temperature (20-25°C or 68-77°F) with excursions permitted between 15-30°C (59-86°F). Protect from light and moisture. Keep in original container with lid tightly closed. The intramuscular formulation should be stored at controlled room temperature and protected from light. After reconstitution, the injection solution may be stored for up to 24 hours at room temperature or up to 7 days under refrigeration. All medications should be kept out of reach of children and pets. Dispose of unused medication properly through medication take-back programs when available.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient needs may vary, and healthcare providers should exercise clinical judgment when prescribing Geodon. Patients should not make changes to their medication regimen without consulting their prescribing physician. Full prescribing information including boxed warnings should be reviewed before administration. The information presented reflects knowledge available at the time of writing and may not encompass all recent developments or individual variations in response.
Reviews
Clinical trials demonstrate Geodon’s efficacy in reducing PANSS scores in schizophrenia by approximately 15-20 points compared to placebo. In bipolar mania studies, Geodon showed significant improvement in Mania Rating Scale scores within 4 days of initiation. Patient reviews often note improved symptom control with relatively minimal weight gain compared to other antipsychotics, though some report sedation and akathisia as challenging side effects. Long-term maintenance studies indicate sustained efficacy in preventing relapse, with approximately 40% of patients maintaining response at one year. The intramuscular formulation receives particular praise for rapid efficacy in acute settings, with noticeable calming effects within 30 minutes of administration in most patients.